Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis

Rawal, Tejal; Parmar, Rajesh; Tyagi, Rajeev K.; Butani, Shital

doi:10.1016/j.colsurfb.2017.03.044

Cited by 107 publications

(41 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This NP formulation has shown sustained drug release until 24 h and no toxicity at both cell and organ. An in vivo study of this formulation showed that rifampicin exhibited increased maximal plasma concentration (C max ), AUC and extended mean residence time (MRT) with the NP formulation [62]. Itraconazole is an anti-fungal drug which, when administered orally, suffers from low solubility.…”

Section: Chitosan In Pulmonary Drug Deliverymentioning

confidence: 99%

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

et al. 2017

View full text Add to dashboard Cite

The focus of this review is to provide an overview of the chitosan based nanoparticles for various non-parenteral applications and also to put a spotlight on current research including sustained release and mucoadhesive chitosan dosage forms. Chitosan is a biodegradable, biocompatible polymer regarded as safe for human dietary use and approved for wound dressing applications. Chitosan has been used as a carrier in polymeric nanoparticles for drug delivery through various routes of administration. Chitosan has chemical functional groups that can be modified to achieve specific goals, making it a polymer with a tremendous range of potential applications. Nanoparticles (NP) prepared with chitosan and chitosan derivatives typically possess a positive surface charge and mucoadhesive properties such that can adhere to mucus membranes and release the drug payload in a sustained release manner. Chitosan-based NP have various applications in non-parenteral drug delivery for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections which will be exemplified in this review. Chitosan shows low toxicity both in vitro and some in vivo models. This review explores recent research on chitosan based NP for non-parenteral drug delivery, chitosan properties, modification, toxicity, pharmacokinetics and preclinical studies.

show abstract

Section: Chitosan In Pulmonary Drug Deliverymentioning

confidence: 99%

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Chitosan nanocomposites have been prepared for anti-TB pulmonary drug delivery. Inhalable rifampicin loaded chitosan nanocomposites have shown negligible in vitro toxicity on murine J774 macrophage cells [99]. Inhalation of the developed formulation by rats lead to a higher maximum drug concentration and a higher residence time in the lungs (up to 24 h) in comparison with a rifampicin commercial powder, explained by the sustained release of rifampicin from the developed formulation.…”

Section: Chitosanmentioning

confidence: 93%

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Miranda

Rodrigues

Domingues

et al. 2018

Materials Science and Engineering: C

View full text Add to dashboard Cite

The growing interest on polymeric delivery systems for pulmonary administration of drugs anticipates a more direct and efficient treatment of diseases such as tuberculosis (TB) that uses the pulmonary route as the natural route of infection. Polymeric microparticles or nano-in-microparticles offer target delivery of drugs to the lungs and the potential to control and sustain drug release within TB infected macrophages improving the efficiency of the anti-TB treatment and reducing side effects. In a dry powder form these inhalable delivery systems have increased stability and prolonged storage time without requiring refrigeration, besides being cost-effective and patient convenient. Thus, this review aims to compile the recent innovations of inhalable polymeric dry powder systems for the delivery of anti-TB drugs exploring the methods of production, aerodynamic characterization and the efficacy of targeted drug delivery systems using in vitro and in vivo models of the disease. Advanced knowledge and promising outcomes of these systems are anticipated to simplify and revolutionize the pulmonary drug delivery and to contribute towards more effective anti-TB treatments.

show abstract

“…Biodegradable and biocompatible PNs are most preferred because they show compatibility with tissues and cells and can be composed of polymers such as poly(lactic-co-glycolic acid) (PLGA), poly-e-caprolactone (PCL), poly(lactic acid) (PLA) and chitosan. Inhalable PNs formulations are advantageous for reason of enhancing solubility and dissolution kinetics of water-insoluble anti-TB drugs and reducing early mucociliary clearance of drugs [9,29]. Inhaled PNs might be exhaled during DPI administration because of their extremely low mass.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future

Mehta

Bothiraja

Kadam

et al. 2018

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Tuberculosis (TB) is a contagious and airborne infectious disease caused by the pathogen Mycobacterium tuberculosis (Mtb). In spite of substantial research efforts, continuous multiple high-dose drug therapy regularly for 4-7 months can impede patient quality of life. The pathology of TB and biology of pulmonary airways permits for a variety of drug delivery strategies and natural route of infection denotes a more logical remedial approach for treatment of TB. Pulmonary delivery is non-invasive, allow easy transcytosis in alveolar region, avoids first-pass metabolism and extensive vascularization facilitates delivery of therapeutic agents to infection site. It also potentially reduces the frequency with dose requirement and linked side effects. Dry powder is a most preferred inhalation option due to their greater physiochemical stability over liquid or suspension based formulations. Dry powder inhalers (DPIs) are easy to handle and appropriate for high-dose formulations. Moreover, the progress of disciplines such as nanotechnology, particle engineering, material science and molecular biology permits further expansion of treatment capability and efficiency. Thus, this article will focus on the role of novel DPIs systems for treatment of TB. This article also contains a dedicated section discussing about technical limitations and clinical challenges with help of strengths, weaknesses, opportunities and threats (SWOT) analysis. Additionally, it will also offer some basic background information for drug repurposing, formulation development and drug delivery systems.

show abstract

Rifampicin loaded chitosan nanoparticle dry powder presents an improved therapeutic approach for alveolar tuberculosis

Cited by 107 publications

References 38 publications

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

Exploring inhalable polymeric dry powders for anti-tuberculosis drug delivery

Potential of dry powder inhalers for tuberculosis therapy: facts, fidelity and future

Contact Info

Product

Resources

About